Sandoz Eyes First-To-Market US Opportunities With Adalvo Deal
Targeting Six Antifungal/Antibiotic, Oncology And Pulmonary Drugs Worth $3bn
Sandoz has struck a deal with Adalvo that will give the company rights to six products in the US – four of which are potential first-to-market opportunities – targeting markets that are collectively worth around $3bn.
